PO107: Radioactive Seed Brachytherapy and Microwave Ablation in the Treatment of Inoperable Stage I Non-Small Cell Lung Cancer.

To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed. [ABSTRACT FROM AUTHOR]